Compare TRDA & KFRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRDA | KFRC |
|---|---|---|
| Founded | 2016 | 1962 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.7M | 499.7M |
| IPO Year | 2021 | 1996 |
| Metric | TRDA | KFRC |
|---|---|---|
| Price | $7.08 | $46.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $21.00 | ★ $39.67 |
| AVG Volume (30 Days) | ★ 677.8K | 176.8K |
| Earning Date | 05-08-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 3.42% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.46 |
| Revenue | $25,421,000.00 | ★ $1,329,007,000.00 |
| Revenue This Year | $39.97 | $2.78 |
| Revenue Next Year | $50.80 | $4.32 |
| P/E Ratio | ★ N/A | $97.20 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.93 | $24.49 |
| 52 Week High | $16.45 | $47.50 |
| Indicator | TRDA | KFRC |
|---|---|---|
| Relative Strength Index (RSI) | 37.64 | 73.29 |
| Support Level | $5.75 | $31.53 |
| Resistance Level | $7.54 | $47.50 |
| Average True Range (ATR) | 0.50 | 1.87 |
| MACD | 0.10 | 0.09 |
| Stochastic Oscillator | 76.46 | 97.48 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Kforce Inc is a solutions firm specializing in technology, finance, accounting, and other professional staffing services. The company operates two business segments: the Technology segment, which provides talent solutions with candidates skilled in areas including systems/applications architecture and development, data management and analytics, business and artificial intelligence, machine learning, project and program management, and network architecture and security. The FA segment offers consultants in traditional finance and accounting roles such as finance, planning and analysis; business intelligence analysis; general accounting; transactional accounting, business and cost analysis; and taxation and treasury. The majority of revenue is earned through the Technology segment.